Immunovant, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Immunovant, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2026 | Dec 31, 2025 | ($110.64M) | Feb 6, 2026 |
| Q2 | 2026 | Sep 30, 2025 | ($126.50M) | Nov 10, 2025 |
| Q3 | 2026 | Sep 30, 2025 | ($126.50M) | Feb 6, 2026 |
| Q3 | 2026 | Jun 30, 2025 | ($120.61M) | Feb 6, 2026 |
| Q2 | 2026 | Jun 30, 2025 | ($120.61M) | Nov 10, 2025 |
| Q1 | 2026 | Jun 30, 2025 | ($120.61M) | Aug 11, 2025 |
| Q3 | 2026 | Dec 31, 2024 | ($111.12M) | Feb 6, 2026 |
| Q3 | 2026 | Sep 30, 2024 | ($109.12M) | Feb 6, 2026 |
| Q2 | 2026 | Sep 30, 2024 | ($109.12M) | Nov 10, 2025 |
| Q1 | 2026 | Jun 30, 2024 | ($87.15M) | Aug 11, 2025 |
| Q2 | 2026 | Jun 30, 2024 | ($87.15M) | Nov 10, 2025 |
| Q3 | 2026 | Jun 30, 2024 | ($87.15M) | Feb 6, 2026 |
| Q3 | 2025 | Dec 31, 2023 | ($51.42M) | Feb 6, 2025 |
| Q3 | 2025 | Sep 30, 2023 | ($58.66M) | Feb 6, 2025 |
| Q2 | 2025 | Sep 30, 2023 | ($58.66M) | Nov 7, 2024 |
| Q2 | 2025 | Jun 30, 2023 | ($73.94M) | Nov 7, 2024 |
| Q3 | 2025 | Jun 30, 2023 | ($73.94M) | Feb 6, 2025 |
| Q1 | 2025 | Jun 30, 2023 | ($73.94M) | Aug 6, 2024 |
| Q3 | 2024 | Dec 31, 2022 | ($63.23M) | Feb 12, 2024 |
| Q2 | 2024 | Sep 30, 2022 | ($47.93M) | Nov 9, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2019 | Sep 30, 2019 | ($419.8K) | Nov 13, 2019 |
| Q2 | 2019 | Jun 30, 2019 | ($92.3K) | Aug 12, 2019 |